Navigation Links
Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
Date:8/4/2008

New Company to be Called Kowa Pharmaceuticals America

NAGOYA, Japan and MONTGOMERY, Ala., Aug. 4 /PRNewswire/ -- Kowa Company, Ltd., a privately-held company headquartered in Nagoya, Japan, today announced the acquisition of ProEthic Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company based in Montgomery, Alabama.

Effective September 1, 2008, ProEthic will change name to Kowa Pharmaceuticals America and will assume responsibility for all sales and marketing functions currently operating in Montgomery, Alabama. ProEthic's clinical development group will transfer to Kowa Research Institute, which is located in Morrisville, North Carolina.

"The opportunity to enter the U.S. pharmaceutical market represents a significant step towards Kowa's vision of creating a global pharmaceutical organization. Pharmaceuticals represent one of Kowa's fastest growing businesses, and we are happy that Kowa Pharmaceuticals America will now be part of that plan," said Yoshihiro Miwa, President and Chief Executive Officer of Kowa. "We are optimistic about the prospects that this acquisition will bring, and we will work closely with the company to ensure its future success."

The first pharmaceutical product to be launched by the new company will be pitavastatin, a novel HMG CoA reductase inhibitor for the treatment of hyperlipidemia. Pitavastatin is sold in Japan, Korea and Thailand under the brand Livalo(R). Pitavastatin has recently completed Phase 3 clinical development in Europe and the United Sates.

"We are excited about the partnership with Kowa and the confidence they have shown in our management team and its ability to grow the company into becoming a leading provider of unique and effective pharmaceutical products," said Carl Whatley, Chief Executive Officer of ProEthic. "We also look forward to the future launch of products from Kowa's rich pipeline, currently in clinical development at Kowa Research Institute."

About Kowa

Since its establishment in 1894, Kowa has grown into a multinational Japanese company actively engaged in various manufacturing and trading activities in the fields of pharmaceutical, life science and information technology, textiles, machinery and various consumer products. During its long history, Kowa has consistently strived to meet the changing needs, and with its continuing entrepreneurial initiative, is determined to meet the needs of future generations. It is this commitment to consistency and initiative in an ever-changing world that Kowa vows to carry forward through each generation.

About ProEthic

ProEthic is a specialty pharmaceutical company focused primarily in the areas of cardiology, pain and migraine. Founded in 2001, the privately held company focuses its efforts on the acquisition, development, licensing, and marketing of pharmaceutical products. Its lead product, Lipofen(R), is indicated as adjunctive therapy to diet to reduce elevated triglycerides and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.


'/>"/>
SOURCE ProEthic Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc.
2. China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd.
3. InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions
4. Pathology Consultants, Inc. Selects PSA, LLC, a MED3OOO Company, as Their Business Partner
5. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
6. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
7. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
8. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
9. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
10. IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... , ... July 18, 2017 , ... Blood centers traditionally ... across the region. Nationally, summer is a struggle for community blood centers as high ... San Antonio Chamber of Commerce is teaming up with the South ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... solutions, today announced safety software company AB Cube has joined its ... segment to advance technology innovation across life sciences and healthcare. Under the ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont ... strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont ... discovery, plant breeding, enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is ...
(Date:7/14/2017)... ... , ... Dr. Joshua Mondlick has introduced the LANAP® protocol to treat gum ... in the Phoenix area. Dr. Mondlick is at the forefront of the future ... to re-grow bone and with significantly less pain than traditional surgery options. , “With ...
Breaking Biology Technology:
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):